Neuromodulation

Electroceuticals/Bioelectric Medicine Markets, 2026 - Pacemaker, ICD, Cochlear Implant, Deep Brain, Spinal Cord, Vagus, Sacral Nerve Stimulators, Ischemia, Epilepsy, Implantable, Noninvasive - ResearchAndMarkets.com

Retrieved on: 
수요일, 7월 28, 2021
General Health, Science, Health, Research, Branches of biology, Medical technology, Biology, Medical devices, Neurotechnology, Biomedical engineering, Prosthetics, Cybernetics, Neuromodulation, Neurostimulation, Implant, Stimulator

The "Electroceuticals/Bioelectric Medicine Market by Product (Pacemaker, ICD, Cochlear Implant, Deep Brain, Spinal Cord, Vagus, Sacral Nerve Stimulators), Application (Ischemia, Epilepsy), Type (Implantable, Noninvasive), End User - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Electroceuticals/Bioelectric Medicine Market by Product (Pacemaker, ICD, Cochlear Implant, Deep Brain, Spinal Cord, Vagus, Sacral Nerve Stimulators), Application (Ischemia, Epilepsy), Type (Implantable, Noninvasive), End User - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • On the other hand, the high cost of electroceutical devices and the requirement of high capital investments are the major factors hampering the growth of this market.
  • In 2020, the cochlear implants segment accounted for the highest growth rate in the electroceuticals market.
  • The global electroceuticals market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.

Evren Technologies receives FDA Breakthrough Device Designation for the Phoenix® - Revolutionary Transcutaneous Auricular Vagus Nerve Therapy to Treat PTSD

Retrieved on: 
월요일, 7월 26, 2021
Branches of biology, Neuroscience, Clinical medicine, Neurotechnology, Autonomic nervous system, Neuroprosthetics, Electrotherapy, Surgery, Vagus nerve stimulation, Vagus nerve, Post-traumatic stress disorder, Neuromodulation

GAINESVILLE, Fla., July 26, 2021 /PRNewswire/ -- Evren Technologies, Inc. announced today that its non-invasive Phoenix earbud device received Breakthrough Device Designation from the U.S. Food and Drug Administration for the treatment of Post-traumatic Stress Disorder (PTSD).

Key Points: 
  • GAINESVILLE, Fla., July 26, 2021 /PRNewswire/ -- Evren Technologies, Inc. announced today that its non-invasive Phoenix earbud device received Breakthrough Device Designation from the U.S. Food and Drug Administration for the treatment of Post-traumatic Stress Disorder (PTSD).
  • 7.5 million Americans seek treatment for PTSD every year and the rates tripled during the COVID shutdown.
  • The Phoenix is an earbud that provides personalized medicine that addresses the underlying autonomic imbalance of PTSD by delivering transcutaneous auricular vagal nerve stimulation (taVNS) in a proprietary closed-loop system.
  • The Phoenix medical device provides personalized medicine in a discreet earbud design that delivers transcutaneous auricular vagal nerve stimulation (taVNS).

CVRx to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call

Retrieved on: 
수요일, 7월 21, 2021
Branches of biology, Neuroscience, Neurotechnology, Neuromodulation, Neurophysiology, Neuropsychology, Pain

MINNEAPOLIS, July 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (CVRx), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter financial and operating results after market close on Wednesday, August 4, 2021.

Key Points: 
  • MINNEAPOLIS, July 21, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (CVRx), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release second quarter financial and operating results after market close on Wednesday, August 4, 2021.
  • The Company will host a conference call to review its results at5:30 p.m. Eastern Timethe same day.
  • To listen to a live webcast, please visit the Investors section of the CVRx website at: ir.cvrx.com/investor-relations.
  • The webcast replay will be available on the CVRx website for 12 months following completion of the call.

electroCore announces Dr. Peter Staats to receive Lifetime Achievement Award from the American Society of Pain and Neuroscience

Retrieved on: 
월요일, 7월 19, 2021
Branches of biology, Nervous system, Medicine, Acute pain, Peter Staats, Pain management, Neurotechnology, North American Neuromodulation Society, American Society of Interventional Pain Physicians, Neuromodulation, Pain Physician, Pain

ROCKAWAY, NJ, July 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the Company), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its cofounder and Chief Medical Officer, Dr. Peter Staats, is to receive a Lifetime Achievement Award at the American Society of Pain and Neuroscience Annual Conference on July 24th, 2021.

Key Points: 
  • ROCKAWAY, NJ, July 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the Company), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its cofounder and Chief Medical Officer, Dr. Peter Staats, is to receive a Lifetime Achievement Award at the American Society of Pain and Neuroscience Annual Conference on July 24th, 2021.
  • Dr. Staats will be honored for his lifelong contribution to field of pain and neuromodulation, advancing the relief from pain through science, clinical education, and research.
  • Dr. Staats has written or co-edited 13 books and over 450 articles, abstracts, monographs, and book chapters on pain medicine in publications that include the Journal of the American Medicine Association, Pain, Anesthesiology, Lancet Neurology and the Journal of Clinical Oncology.
  • Dr. Staats is the former President of the North American Neuromodulation Society, American Society of Interventional Pain Physicians, New Jersey Society of Interventional Pain Physicians, and the Southern Pain Society.

Nevro Announces FDA Approval of its 10 kHz High Frequency Spinal Cord Stimulation Therapy for Treatment of Chronic Pain Associated with Painful Diabetic Neuropathy (PDN)

Retrieved on: 
월요일, 7월 19, 2021
Branches of biology, Neuroscience, Neurotechnology, Neurophysiology, Pain, Acute pain, Sensory systems, Neuromodulation, Spinal cord stimulator, Peripheral neuropathy, Spinal cord, Neurostimulation

This approval is specific to Nevro's unique 10 kHz stimulation, and Nevro now has the only spinal cord stimulation system approved by the FDA with a specific indication to treat PDN.

Key Points: 
  • This approval is specific to Nevro's unique 10 kHz stimulation, and Nevro now has the only spinal cord stimulation system approved by the FDA with a specific indication to treat PDN.
  • Study participants demonstrated significantly improved and sustained outcomes with 10 kHz Spinal Cord Stimulation (SCS), including substantial, sustained pain relief and improved health-related quality of life.
  • Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain.
  • Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: ARandomized Clinical Trial.JAMA Neurol.2021 Jun 1;78(6):687-698. doi:10.1001/jamaneurol.2021.0538.

Nalu Medical Announces Scientific Presentations at 2021 North American Neuromodulation Society (NANS) Mid-Year Meeting

Retrieved on: 
목요일, 7월 15, 2021
Branches of biology, Nervous system, Medicine, Pain, Neurotechnology, Acute pain, Nociception, Neuromodulation, Neurostimulation, Nalu, Neuropathic pain, Pain management

CARLSBAD, Calif., July 15, 2021 /PRNewswire-PRWeb/ --Nalu Medical, Inc. ("Nalu"), a California-based company that has successfully miniaturized neurostimulation implants for chronic intractable pain management indications, announced that the scientific presentation schedule during the 2021 North American Neuromodulation Society (NANS) Mid-Year Meeting in Orlando, Florida will include three abstract submissions all selected for oral presentations.

Key Points: 
  • CARLSBAD, Calif., July 15, 2021 /PRNewswire-PRWeb/ --Nalu Medical, Inc. ("Nalu"), a California-based company that has successfully miniaturized neurostimulation implants for chronic intractable pain management indications, announced that the scientific presentation schedule during the 2021 North American Neuromodulation Society (NANS) Mid-Year Meeting in Orlando, Florida will include three abstract submissions all selected for oral presentations.
  • We are a medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic neuropathic pain.
  • Our Nalu Neurostimulation System, or Nalu System, delivers gentle electrical pulses to the nervous system to modulate pain signals to the brain.
  • Nalu, the Nalu logo and nPower are trademarks of Nalu Medical, Inc.
    1.

Dr. Robert Moghim to Participate in Clinical Trial for Knee Pain Using Freedom Peripheral Nerve Stimulator

Retrieved on: 
목요일, 7월 15, 2021
Branches of biology, Medicine, Clinical medicine, Neurotechnology, Skeletal disorders, Pain, Acute pain, Neuromodulation, Neurophysiology, Stimulator, Osteoarthritis, Arthritis

DENVER, July 15, 2021 /PRNewswire/ --Dr. Robert Moghim at Colorado Pain Care has recently been approved to participate in a clinical trial on Peripheral Nerve Stimulation for Knee Pain.

Key Points: 
  • DENVER, July 15, 2021 /PRNewswire/ --Dr. Robert Moghim at Colorado Pain Care has recently been approved to participate in a clinical trial on Peripheral Nerve Stimulation for Knee Pain.
  • This study is designed to assess the effectiveness of the Freedom Peripheral Nerve Stimulator (PNS) System for treating chronic knee pain caused by osteoarthritis.
  • Dr. Moghim will be enrolling 10 participants for this study that is expected to last 2 years.
  • The results are intended to help people with arthritic knee pain in the future.

Groundbreaking Study Establishes Non-Surgical Treatment Modality to Improve Function in Children With Cerebral Palsy

Retrieved on: 
화요일, 7월 13, 2021
Branches of biology, Neuroscience, Neurotechnology, Neuromodulation, Neurophysiology, Neuropsychology, Pain, Cerebral palsy, PR2

Transcutaneous Spinal Neuromodulation Reorganizes Neural Networks in Patients with Cerebral Palsy discusses how spinal neuromodulation and activity-based rehabilitation triggers neural network reorganization and enhances sensory-motor performances involving the lower limbs, the trunk and the upper limbs.

Key Points: 
  • Transcutaneous Spinal Neuromodulation Reorganizes Neural Networks in Patients with Cerebral Palsy discusses how spinal neuromodulation and activity-based rehabilitation triggers neural network reorganization and enhances sensory-motor performances involving the lower limbs, the trunk and the upper limbs.
  • Cerebral palsy affects over 17 million individuals worldwide and is the most common motor disability in childhood.
  • This study demonstrates dramatic effects of neurostimulation on children with CP.
  • We saw a considerable improvement in head and trunk strength with the very first use of SCONE, said Dawn Hamilton.

CVRx Welcomes Veteran Life Science Industry Leader Martha Shadan to its Board of Directors

Retrieved on: 
월요일, 7월 12, 2021
Branches of biology, Neuroscience, Neuromodulation, Neurophysiology, Neuropsychology, Neurotechnology, Pain, Zimmer Biomet Robotics

With more than three decades of experience as a business leader in the life science industry, Shadan brings a long track record of success in helping to commercialize medtech innovations for both start-up and large companies.

Key Points: 
  • With more than three decades of experience as a business leader in the life science industry, Shadan brings a long track record of success in helping to commercialize medtech innovations for both start-up and large companies.
  • Prior to joining Rotation Medical, Shadan was the president of the Trauma Division at Zimmer, where she managed the P&L for the global business.
  • I am honored to serve on the CVRx board, says Shadan.
  • CVRx is dedicated to improving patient outcomes, quality of life, and overall cardiovascular health via novel baroreceptor neuromodulation therapies.

Neurolief Announces Exclusive Licensing Agreement with NeuroFront for Development and Commercialization of Relivion® in Greater China and South Korea

Retrieved on: 
수요일, 7월 7, 2021
Technology, Mental health, Medical devices, Other Technology, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Branches of biology, Neuroscience, Neurotechnology, Health sciences, Neurophysiology, Neuropsychology, Pain, Neuromodulation, Clinical trial

We are confident that the NeuroFront teams compelling expertise will accelerate the development and commercialization of Relivion in key Asian markets.

Key Points: 
  • We are confident that the NeuroFront teams compelling expertise will accelerate the development and commercialization of Relivion in key Asian markets.
  • Relivion is a non-invasive brain neuromodulation device that is placed around the head and delivers stimulation to the occipital and trigeminal nerves.
  • The FDA marketing clearance is based on the results of a multi-center, prospective, randomized, double-blind, placebo-controlled clinical study.
  • Neurolief will begin a multi-center pivotal trial of Relivion in depression called the MOOD trial, starting in the fall of 2021.